EISAI CO

EISAI CO logo
🇯🇵Japan
Ownership
Public
Established
1941-12-06
Employees
11K
Market Cap
$12B
Website
http://www.eisai.co.jp
Clinical Trials
Related News

Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

Phase 2
Completed
Conditions
Biliary Tract Cancer
Interventions
Drug: Lenvatinib
First Posted Date
2015-10-19
Last Posted Date
2020-12-23
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
29
Registration Number
NCT02579616

Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)

Phase 1
Completed
Conditions
Carcinoma, Renal Cell
Interventions
Drug: Lenvatinib
Drug: Everolimus
First Posted Date
2015-05-27
Last Posted Date
2019-03-19
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
7
Registration Number
NCT02454478
Locations
🇯🇵

Eisai Trial Site #1, Tokyo, Japan

🇯🇵

Eisai Trial Site #2, Tokyo, Japan

Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients

Completed
Conditions
Insomnia
Interventions
Drug: Eszopiclone
First Posted Date
2015-05-27
Last Posted Date
2018-09-07
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
438
Registration Number
NCT02455271

Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients

Completed
Conditions
Insomnia
Interventions
Drug: Eszopiclone
First Posted Date
2015-05-25
Last Posted Date
2018-09-07
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
4876
Registration Number
NCT02452684

Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).

First Posted Date
2015-05-19
Last Posted Date
2018-07-11
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
591
Registration Number
NCT02448784

Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

Completed
Conditions
Thyroid Neoplasms
Interventions
Drug: Lenvatinib
First Posted Date
2015-04-30
Last Posted Date
2020-01-09
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
629
Registration Number
NCT02430714

An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects

Phase 3
Completed
Conditions
Epilepsy
Interventions
Drug: Perampanel
First Posted Date
2015-04-28
Last Posted Date
2018-07-02
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
7
Registration Number
NCT02427607

Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Aspirin

First Posted Date
2015-04-22
Last Posted Date
2018-08-28
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
1568
Registration Number
NCT02423187

Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.

First Posted Date
2015-02-25
Last Posted Date
2018-07-13
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
651
Registration Number
NCT02371174

A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)

First Posted Date
2015-01-26
Last Posted Date
2019-01-08
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
160
Registration Number
NCT02345213
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy